---
figid: PMC5813752__onco12312-fig-0003
figtitle: Schema of ERBB2
organisms:
- Homo sapiens
pmcid: PMC5813752
filename: onco12312-fig-0003.jpg
figlink: /pmc/articles/PMC5813752/figure/onco12312-fig-0003/
number: F3
caption: 'Schema of ERBB2. (A): The G660D mutation is located in the ERBB2 transmembrane
  domain. Other missense or in‐frame mutations are also shown. The MEK/ERK signaling
  pathway is stimulated by dimerization of ERBB2. (B): Mechanisms of monoclonal antibodies,
  such as trastuzumab, and tyrosine kinase inhibitors (TKIs), such as afatinib, for
  ERBB2. Trastuzumab and other monoclonal antibodies bind to the ECD and prevent dimerization
  of ERBB2, whereas afatinib and other TKIs bind to the kinase domain (KD) and inhibit
  ERBB2. The KD is activated in ERBB2 KD‐ or TMD‐mutant tumors regardless of ECD status.Abbreviations:
  ECD, extracellular domain; ERBB2, avian erythroblastic leukemia viral oncogene homolog
  2 (erb‐b2 receptor tyrosine kinase 2); ERK, extracellular signal‐regulated kinases;
  MEK, MAPK‐ERK kinase; Mut, mutation; RAF, rapidly accelerated fibrosarcoma proto‐oncogene,
  serine/threonine kinase; RAS, rat sarcoma viral oncogene homolog; TMD, transmembrane
  domain.'
papertitle: Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane
  Domain Mutations G660D and V659E.
reftext: Hiromasa Yamamoto, et al. Oncologist. 2018 Feb;23(2):150-154.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8708324
figid_alias: PMC5813752__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5813752__F3
ndex: 5bb0b34e-de9d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5813752__onco12312-fig-0003.html
  '@type': Dataset
  description: 'Schema of ERBB2. (A): The G660D mutation is located in the ERBB2 transmembrane
    domain. Other missense or in‐frame mutations are also shown. The MEK/ERK signaling
    pathway is stimulated by dimerization of ERBB2. (B): Mechanisms of monoclonal
    antibodies, such as trastuzumab, and tyrosine kinase inhibitors (TKIs), such as
    afatinib, for ERBB2. Trastuzumab and other monoclonal antibodies bind to the ECD
    and prevent dimerization of ERBB2, whereas afatinib and other TKIs bind to the
    kinase domain (KD) and inhibit ERBB2. The KD is activated in ERBB2 KD‐ or TMD‐mutant
    tumors regardless of ECD status.Abbreviations: ECD, extracellular domain; ERBB2,
    avian erythroblastic leukemia viral oncogene homolog 2 (erb‐b2 receptor tyrosine
    kinase 2); ERK, extracellular signal‐regulated kinases; MEK, MAPK‐ERK kinase;
    Mut, mutation; RAF, rapidly accelerated fibrosarcoma proto‐oncogene, serine/threonine
    kinase; RAS, rat sarcoma viral oncogene homolog; TMD, transmembrane domain.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - ECD
  - SEM1
  - MMUT
  - TTN
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - 888888Y
  - Lapatinib
  - Afatinib
  - TMD
---
